Biotage AB (Biotage) is a provider of innovative products and solutions in the areas of analytical chemistry, medicinal chemistry, peptide synthesis, separation, and purification. It also supplies instruments, reagents, and services to its customer groups in the life sciences sector. In January 2022, the company has reclassified its business operations. The company new classification has six product categories such as Small Molecules and Synthetic Therapeutics, Analytical Testing, Water and Environmental Testing, Scale up, Diagnostics and Biologics and Advanced Therapeutics.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Biotage’s R&D activities focuses on product improvement and to develop innovative new technology for next-gen products. In FY2022, the company spent SEK109 million on its R&D, which as a percentage of the company's revenue stood at 6.96% and increased by 19.8% YoY. During the FY2022, the company has allocated one-tenth of the budget towards innovative research on new concepts, and for collaborations with academic research groups. As of December 2022, the company had 282registered patents and 75 patent applications which are divided 67 patents families. It also comprises of 15 new granted and 6 new patent application.